- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- The 10 Poorest States in America
Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.
Inuit prints from northern Canada offer a beautiful -- and affordable -- investment.
The first part of the year was solid for new biotechs and health stocks.
Fans say the company is too big to fail, but it's also too big to grow much without developing more hits.
The drug is approved by the FDA for younger patients.
Frank D'Amelio will join the company from Alcatel-Lucent.
Reclast is a once-a-year treatment.
It gets bad news from the FDA and pulls a hepatitis C drug candidate.
The company will sell $350 million in debt, warrants and stock.